TICKERNOMICS Sign up
Last Update: 2024-12-27 15:22:35
Ascendis Pharma A/S ( ASND ) https://ascendispharma.com
140.31USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Denmark
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ASND
10.17%
SPY
32.66%
ASND
4.18%
SPY
108.59%
ASND
3.88%
SPY
302.52%
ASND
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
8348.53
8530.74
0.12
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-17.25
34.48
-76.81
-5.90
0.00
-17.48
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-167.28
80.63
-240.77
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.9328
-71.07
-59.53
0.71
Other Earnings and Cash Flow Stats:
Ascendis Pharma A/S ( ASND ) Net Income TTM ($MM) is -484.07
Ascendis Pharma A/S ( ASND ) Operating Income TTM ($MM) is -447.06
Ascendis Pharma A/S ( ASND ) Owners' Earnings Annual ($MM) is -448.76
Ascendis Pharma A/S ( ASND ) Current Price to Owners' Earnings ratio is -15.62
Ascendis Pharma A/S ( ASND ) EBITDA TTM ($MM) is -432.84
Ascendis Pharma A/S ( ASND ) EBITDA Margin is -240.77%
Capital Allocation:
Ascendis Pharma A/S ( ASND ) has paid 0.00 dividends per share and bought back -3.487716 million shares in the past 12 months
Ascendis Pharma A/S ( ASND ) has increased its debt by 161.7611268833 million USD in the last 12 months
Capital Structure:
Ascendis Pharma A/S ( ASND ) Interest-bearing Debt ($MM) as of last quarter is 880
Ascendis Pharma A/S ( ASND ) Annual Working Capital Investments ($MM) are -132
Ascendis Pharma A/S ( ASND ) Book Value ($MM) as of last quarter is -109
Ascendis Pharma A/S ( ASND ) Debt/Capital as of last quarter is -811%
Other Balance Sheet Stats:
Ascendis Pharma A/S ( ASND ) has 698 million in cash on hand as of last quarter
Ascendis Pharma A/S ( ASND ) has 936 million of liabilities due within 12 months, and long term debt 880 as of last quarter
Ascendis Pharma A/S ( ASND ) has 59 common shares outstanding as of last quarter
Ascendis Pharma A/S ( ASND ) has 0 million USD of preferred stock value
Academic Scores:
Ascendis Pharma A/S ( ASND ) Altman Z-Score is -0.53 as of last quarter
Ascendis Pharma A/S ( ASND ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Ascendis Pharma A/S ( ASND ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Ascendis Pharma A/S ( ASND ) for the amount of $ on
0.81% of Ascendis Pharma A/S ( ASND ) is held by insiders, and 119.63% is held by institutions
Ascendis Pharma A/S ( ASND ) went public on 2015-01-28
Other Ascendis Pharma A/S ( ASND ) financial metrics:
FCF:-479.53
Unlevered Free Cash Flow:-584.69
EPS:-7.11
Operating Margin:-167.28
Gross Profit Margin:80.63
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:391.20
Beta:0.71
Buffet's Owners Earnings:-448.76
Price to Owner's Earnings:-15.62
About Ascendis Pharma A/S ( ASND ) :
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/ for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.